Vitrolife AB (OSTO:VITR) Debt-to-Equity : 0.16 (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Vitrolife AB Debt-to-Equity?

Vitrolife AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr119 Mil. Vitrolife AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr1,951 Mil. Vitrolife AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr13,231 Mil. Vitrolife AB's debt to equity for the quarter that ended in Mar. 2024 was 0.16.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Vitrolife AB's Debt-to-Equity or its related term are showing as below:

OSTO:VITR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.05 Max: 0.16
Current: 0.16

During the past 13 years, the highest Debt-to-Equity Ratio of Vitrolife AB was 0.16. The lowest was 0.01. And the median was 0.05.

OSTO:VITR's Debt-to-Equity is ranked better than
56.84% of 709 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs OSTO:VITR: 0.16

Vitrolife AB Debt-to-Equity Historical Data

The historical data trend for Vitrolife AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vitrolife AB Debt-to-Equity Chart

Vitrolife AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.03

0.16

0.13

0.16

Vitrolife AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.13	0.13	0.12	0.16	0.16

Competitive Comparison of Vitrolife AB's Debt-to-Equity

For the Medical Devices subindustry, Vitrolife AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vitrolife AB's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Vitrolife AB's Debt-to-Equity falls into.

Vitrolife AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Vitrolife AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(147	+	1942)	/	12722
	=	0.16

Vitrolife AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(119	+	1951)	/	13231
	=	0.16

Vitrolife AB (OSTO:VITR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Vitrolife AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Vitrolife AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vitrolife AB (OSTO:VITR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vitrolife AB (OSTO:VITR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

0YAY:UK VTFN:Germany

Address

Box 9080, Gothenburg, SWE, 400 92

Website

https://www.vitrolife.com

Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive advanced support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction.

Vitrolife AB (OSTO:VITR) Headlines

No Headlines